Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript March 19, 2026 Taysha Gene Therapies, Inc. beats earnings expectations. Reported EPS is $-0.08711, expectations were ...

Management indicated the pivotal and ASPIRE trials are "on track to complete dosing in the second quarter of 2026." The company expects to initiate BLA-enabling process performance qualification (PPQ) ...

Taysha Gene Therapies (NASDAQ:TSHA) highlighted clinical, regulatory, and commercial progress for its lead Rett syndrome gene ...

Joining me on today’s call are Sean Nolan, Taysha Gene Therapies, Inc.'s Chief Executive Officer; Sukumar Nagendran, ...

Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate AS ...

Salanersen, a treatment candidate for spinal muscular atrophy (SMA) now in clinical testing, is safe and was shown to stabilize or improve motor function over at least one year of follow-up in ...

Insmed has launched a first-in-human Phase 1 trial testing its experimental ALS gene therapy INS1202 in people with the disease.

TerSera Therapeutics LLC today announced that it has completed the previously announced sale of its Infusion Specialty Therapies Business Unit (IST), including two specialty medications, Prialt(R) ...

Following initiation of the rolling submission in December 2025, Sangamo has now submitted the preclinical and clinical modules to the FDA for review. Rolling submission allows for completed modules ...

Camp4 Therapeutics FY25 GAAP EPS missed expectations, but ended the year with a robust cash position. Check out why CAMP ...

In recent days, Stoke Therapeutics and Biogen reported that data on the investigational Dravet syndrome medicine zorevunersen were published in The New England Journal of Medicine, alongside Stoke’s ...